Episode Summary
Executive Summary: The episode traces how ivermectin went from a promising repurposed drug candidate to a politicized COVID controversy. It follows early desperation in ICUs, a flawed Egyptian paper that helped fuel enthusiasm, and student-led forensic analysis that exposed likely fraud and broader quality problems. The best later trials found no meaningful benefit, yet some clinicians remain convinced and see a conspiracy.
Main Topics: Early pandemic desperation and treatment hunger (Priority: 5/5): Doctors, especially in ICUs, were facing severe COVID with few proven treatments and were eager to try anything that might help patients survive. Steroids as a precedent for repurposed drugs (Priority: 4/5): Pierre Corey’s early push for steroids was initially criticized, then validated by trial results, reinforcing the idea that repurposed drugs could matter in COVID. Ivermectin gains momentum through early and low-quality evidence (Priority: 5/5): Lab findings and early human studies, especially a large Egyptian preprint, made ivermectin look highly effective and drove widespread enthusiasm. Fraud investigation into the El Ghazary paper (Priority: 5/5): Jack Lawrence and collaborators uncovered plagiarism, copied-and-pasted data, impossible death timing, and signs that the study’s results were fabricated or at least deeply unreliable. Public politicization and mass uptake (Priority: 4/5): Pierre Corey’s Senate testimony and appearance on Joe Rogan propelled ivermectin into mainstream debate, contributing to soaring prescriptions and even veterinary misuse. Higher-quality evidence fails to show benefit (Priority: 5/5): As larger, better-controlled trials emerged, especially the Together study, the case for ivermectin weakened substantially, with no clear reduction in hospitalization, recovery time, or death. Science, bias, and conspiracy interpretations (Priority: 4/5): The episode contrasts researchers’ view that skepticism and better data explain the reversal with Corey’s view that institutions are suppressing repurposed drugs for financial reasons.
Key Arguments: Early enthusiasm for ivermectin came from lab studies and preliminary human trials, but early positive studies were often small, unblinded, or methodologically weak. The Egyptian El Ghazary preprint was central to ivermectin’s reputation, but forensic review found plagiarism and raw-data inconsistencies consistent with deliberate fabrication. Once the flawed studies are removed from reviews, the apparent mortality benefit shrinks or disappears. The best evidence, including the large blinded Together trial, shows ivermectin does not meaningfully reduce hospitalization, symptom duration, or death in COVID. Corey argues the drug worked in his clinical experience and that the medical establishment is biased against inexpensive repurposed medicines. Investigators say they applied similar scrutiny to ivermectin and other drugs, and that their concerns were not unique to ivermectin, but the strongest ivermectin-positive studies were disproportionately the dodgiest. The story illustrates how desperation, politics, social media, and weak evidence can turn a treatment candidate into a cultural flashpoint.
Data Points: Deaths in severe COVID arm of the El Ghazary paper: Patients were reported to die on the same three dates repeatedly - Jack Lawrence and collaborators found impossible clustering in the raw data, suggesting copy-paste manipulation Death count in mild COVID arm: 0 deaths in raw data vs 4 deaths reported in paper - A key inconsistency Jack discovered when checking the source dataset Reported improvement in severe COVID patients: 94% got better - Claim from the Egyptian preprint that helped drive ivermectin enthusiasm Review estimate of survival benefit: Over 50% improvement in survival - A review of around 20 randomized trials that initially impressed NIH-linked reviewer Roy Gulick Revised benefit after removing the El Ghazary paper: 38% benefit - The review’s apparent effect size shrank after excluding the fraudulent/tainted study Final result after excluding more questionable studies: No significant benefit - The review no longer showed a trustworthy ivermectin effect Together Study sample size: More than 1,000 people - Large randomized, double-blind trial that found ivermectin did not work for COVID US ivermectin spending in one week of August: More than $2 million - Insurance payouts for COVID-related ivermectin prescriptions Recent US prescriptions: Around 200,000 prescriptions in the last COVID wave in January - Shows continued use despite weak evidence Number of citations in the episode: 141 - Mentioned by the production team in the outro
Pivotal Quotes: "We have a solution to this crisis. There is a drug that is proving to be of miraculous impact." — Pierre Corey: Senate hearing testimony that helped make ivermectin famous "This is the most obviously, incontrovertibly deliberate fraud I've ever seen." — Kyle Sheldrick: Assessment of the El Ghazary paper after examining raw data anomalies "If you polish a turd, it's still a turd." — Roy Gulick: Explaining why combining low-quality studies can still produce an untrustworthy conclusion
Implications: The episode suggests ivermectin is not a COVID breakthrough and that early hype was driven by weak or fraudulent evidence. It also shows how quickly medical uncertainty can become politicized, affecting public trust, prescribing, and vaccine attitudes.
About Science Vs
There are a lot of fads, blogs and strong opinions, but then there’s SCIENCE. Science Vs is the show from Spotify Studios that finds out what’s fact, what’s not, and what’s somewhere in between. We do the hard work of sifting through all the science so you don't have to and cover everything from 5G and ADHD, to Fluoride and Fasting Diets.